{"id":1956,"date":"2022-03-25T20:53:09","date_gmt":"2022-03-25T20:53:09","guid":{"rendered":"https:\/\/linksus.net\/will-the-next-variant-look-like-omicron-medical-news-today\/"},"modified":"2022-03-25T20:53:09","modified_gmt":"2022-03-25T20:53:09","slug":"will-the-next-variant-look-like-omicron-medical-news-today","status":"publish","type":"post","link":"https:\/\/linksus2.linksus.net\/index.php\/2022\/03\/25\/will-the-next-variant-look-like-omicron-medical-news-today\/","title":{"rendered":"Will the next variant look like Omicron? – Medical News Today"},"content":{"rendered":"

All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our <\/em>coronavirus hub<\/a> and follow our <\/em>live updates page<\/a> for the most recent information on the COVID-19 pandemic.<\/em>
It is unlikely that Omicron will end the pandemic as we know it or be the last SARS-CoV-2 variant that we encounter. We are already seeing that BA.2 \u2014 a sublineage of Omicron, or its sister variant \u2014 is outcompeting the BA.1 sublineage in parts of the world.
Although it is not a new or separate variant, the BA.2 subvariant has reignited discussions about how the next variant will look.
Based on projections so far, some scientists believe that the next variant after Omicron will likely attenuate. However, some argue that this is wishful thinking and the possibility of a strain that is both more transmissible and more deadly is very real.
All in all, they stress the need to consider all scenarios\u2014best and worst.
Dr. Semih Tareen, Ph.D.<\/a>, a virologist and senior director of gene therapy at Sana Biotechnology, Seattle, told Medical News Today<\/em> that it was natural for viruses to mutate and that it was a \u201cnormal and part of an evolutionary advantage for how they create diversity through quasispecies.\u201d
He reiterated that Omicron came about as a result of one of the thousands of mutations and combinations of mutations that SARS-CoV-2 has undergone and continues to undergo throughout the pandemic.
Tareen said that authorities only designated Omicron as a variant of concern because of its increased infectivity and regional dominance, noting that there were many mutations before it.
\u201cOmicron is certainly not the last variant. At this point, it would be hard to tell what the next variants will be like.\u201d
\u2013 Semih Tareen, Ph.D.
\u201cIt is true that Omicron is not likely going to be the last variant we encounter, but there is no definitive way to predict what the next one be like. One would hope as we move into new normal that SARS-CoV-2 becomes an endemic virus like the flu<\/a> that just circulates around worse in certain times of the year in places,\u201d said Priya Luthra<\/a>, a molecular virologist and scientific director who has just moved to the Infectious Diseases Research Unit at GlaxoSmithKline.
Not necessarily, say scientists.
A virus naturally mutates. SARS-CoV-2 has constantly evolved to become fitter, increasing its ability to infect more people, evade infection-acquired or vaccine-induced immunity, or both.
Scientists such as Peter V. Markov<\/a>, Nikolaos I. Stilianakis<\/a>, and Aris Katzourakis<\/a> have argued<\/a><\/hl-trusted-source> that Omicron appearing less severe could be a lucky coincidence. They say the rapid emergence of new variants through antigenic evolution will likely \u201cproduce new variants that may escape immunity and be more severe.\u201d
It is true that SARS-CoV-2 is not under pressure to evolve toward becoming less virulent, hence it is not possible to say whether the next strain\u2019s mutations will make it so. As these mutations are random, such changes can go either way.
For example, the Alpha variant caused more severe disease than the original wild-type virus, and Delta was also more severe than Alpha.
Dr. John Roberts, lead of International Medical Corps\u2019 U.S. Programs and Emergency Response, told MNT<\/em>:
\u201cIt\u2019s difficult to say what the next variant will look like. In general, these types of viruses become more contagious but less deadly over time. However, that is not always the case.\u201d
Dr. Roberts said it was likely that both vaccination and previous infection would provide varying degrees of protection against infection and severe outcomes.
However, he stressed that it would depend on \u201ca number of factors, including the mutation and the general health of the population.\u201d
Scientists are waiting to see whether SARS-CoV-2 will start to evolve more predictably and become more like other respiratory viruses. One theory is that it could become similar to the common cold, while another is that it could evolve into something more dangerous<\/a>, as other infectious diseases have done.
Dr. Roberts said the COVID-19 pandemic will probably \u201cmove to epidemic and then endemic stages, with likely seasonal fluctuations, similar to the flu.\u201d
\u201cThese fluctuations may or may not be considered epidemics\/pandemics, depending on how widely spread the disease is, how quickly it spreads, whether many people are infected at the same time, and other factors that will differ from year to year and that will depend on virus characteristics, as well as social factors,\u201d he told MNT<\/em>.
Researchers are currently working on a number of projections and models<\/a> to predict future variants.
What we have seen so far is that Omicron is outcompeting previous variants. One of its newer subvariants, BA.2,<\/a> also seems to be on course to outcompete BA.1 in countries such as Denmark and Nepal<\/a>.
In comparison with its predecessors, Omicron is the most different variant and the one that is best at partially evading the current vaccines.
Prof. Mark Woolhouse<\/a>, professor of infectious disease epidemiology at Edinburgh University, highlights<\/a> that \u201cthe Omicron variant did not come from the Delta variant.\u201d
\u201c[Omicron] came from a completely different part of the virus\u2019s family tree. And since we don\u2019t know where in the virus\u2019s family tree a new variant is going to come from, we cannot know how pathogenic it might be. It could be less pathogenic, but it could just as easily be more pathogenic,\u201d he says.
As evident from Alpha, Delta, and Omicron, SARS-CoV-2 did not evolve in a linear manner<\/a>. This means the next variant will likely not come from a lineage that is prevailing at the time.
Of all the variants so far, Dr. Tareen singled out Omicron and its recent BA.2 subvariant as representing \u201cclusters that are unique and distant from the Alpha, Beta, Delta variant clusters.\u201d
\u201cWhat this means is that future variants could arise from an Omicron (also known as BA.1) cluster, from a BA.2 cluster, or from a Delta cluster (clusters here refer to subvariants that arise from these major variants). Only time will tell, but at the moment, these are the prominent variants in most parts of the globe,\u201d he said.
Although a much less likely scenario, Dr. Tareen said that it was also \u201cstill plausible that new variants could arise from a reverse-zoonotic event.\u201d
He gave examples of recent reports about scientists finding Omicron in non-human hosts, such as deers.
\u201c[These] could generate new variants and represent a different lineage if they were to re-enter human circulation,\u201d he said.
Many countries, including the U.K. and Denmark, among others, have started to scale back mitigation measures against COVID-19. However, lifting measures such as physical distancing and mask-wearing too early could give the virus more opportunity to circulate and mutate.
In an open letter<\/a> criticizing Prime Minister Boris Johnson\u2019s decision to end all protective measures against COVID-19, some of the U.K.\u2019s leading scientists warned that increased and uncontrolled SARS-CoV-2 transmission would bring new risks. More than 3,700 other scientists have added their signatures.
\u201cEvery strain of SARS-CoV-2 to date has failed to reach population saturation. Instead, each has been replaced by a new variant that is more transmissible, more immunity-escaping, or both. This pattern will likely be repeated,\u201d they wrote.
In that regard, for a better chance of fighting newer variants, scientists believe we need to reduce transmission through a \u201cvaccines plus\u201d approach, which includes mitigation measures such as mask-wearing.
According to an early February statement<\/a><\/hl-trusted-source> from the regional director of the World Health Organization (WHO), Hans Kluge, it is \u201cplausible that [Europe] is \u201cmoving toward a kind of pandemic endgame.\u201d This is plausible due to the following factors<\/a>: \u201ca large capital of vaccine-derived and natural immunity to Omicron, a favorable seasonality pause, and a lower severity of the Omicron variant.\u201d
This stance is based on the assumption that the pandemic will enter an endemic stage. However, not many scientists share Kluge\u2019s optimism.
\u201cThis is very premature; we are still in a pandemic surge. There are different scenarios that the pandemic can play out, and we may get to endgame by reaching certain goals such as [vaccinating] 70% of the global population, including children and vulnerable populations, [and] improving testing and surveillance of [the] virus,\u201d said Prof. Luthra.
Endemicity, scientists say, will happen when we can tolerate the burden the virus is placing on healthcare systems and societies. The current burden, for which measures include daily cases, hospitalizations, and deaths, is too high.
Reaching endemicity will likely not look the same for all countries. Some may still be going through an active phase in the pandemic, while others will have the virus under control.
\u201cTill then, we need to disrupt the transmission of the virus by following good masking practice, avoiding crowds, and [incorporating] good ventilation, as we have learned in this pandemic that these interventions work,\u201d Prof. Luthra stressed.
She said that having regular revaccination via boosters and getting kids vaccinated would play a pivotal role in reaching endemicity.
Low levels of vaccination, waning immunity, and vaccine inequity in a globalized world could increase transmission and aid viral mutations.
Dr. Tareen said one of the biggest challenges right now is vaccine inequity.
\u201cWe are lucky that there are vaccines and that there are parts of the world where vaccination campaigns and willingness to be vaccinated have resulted in high vaccination rates with boosters. But we do not live in a world of closed borders,\u201d he said.
Prof. Luthra said that COVID-19 vaccines had provided significant protection against the Delta and Omicron variants with boosters.
\u201cOne would hope that if the vast majority of the population is vaccinated, even with a more virulent variant in the future, we don\u2019t get nearly as sick,\u201d she said.
Dr. Tareen also touched on how vaccination- and infection-acquired immunity could affect the next variant.
\u201cIt is theoretically possible that a more virulent strain may come along, but with the ongoing increase of immunity, both from vaccinations and infections, the chances of a more virulent strain wreaking havoc is decreasing,\u201d Dr. Tareen told MNT<\/em>.
However, with more widespread immunity and the number of susceptible individuals dwindling, some scientists argue that the next variant may be more virulent with a better ability to reinfect.
\u201cOnce Omicron infects the majority of individuals, the next variant will need to be as antigenically different from Omicron and previous VOCs as possible to overcome immunity against them,\u201d say Prof. Markov and his colleagues<\/a><\/hl-trusted-source>.
\u201cWe know so far that vaccination has protected people from severe disease and deaths. Even if [a] more virulent variant comes along, we would hope that vaccines continue to provide protection,\u201d said Prof. Luthra.
High vaccination rates should also keep death and hospitalization rates down.
\u201cThe good news is that so far, approved vaccines, with the appropriate boosters, have demonstrated efficacy to all variants so far, including Omicron,\u201d said Dr. Tareen.
\u201cWe should remind ourselves that the main goal of these vaccines is to decrease the risk of serious illness. As long as this is the case, we should continue to see declining hospitalizations in regions where fully vaccinated\/boosted rates are high,\u201d he added.
Dr. Roberts said that any changes in the current vaccines\u2019 effectiveness will depend on the set of mutations the new variant undergoes.
He said that these mutations may or may not affect the effectiveness of vaccines. However, assuming that a new mutation does affect the protection that vaccines provide, it is likely that companies will elect to update the formula.
\u201cThe advantage of newer mRNA technology is that these changes will likely be able to be made more quickly,\u201d Dr. Roberts said.
Updating vaccines has been something that scientists have been working on since earlier variants of SARS-CoV-2 emerged.
Researchers have conducted trials to assess the effectiveness of tweaked formulas for the Delta variant, for example. These demonstrated to scientists that variant-specific boosters were unnecessary<\/a>. However, research is underway for Omicron-specific boosters.
Dr. Tareen said that many biotech companies had revisited the concept of updated vaccines with Omicron, but he pointed out the following caveat:
\u201cRecent data with the Omicron-updated vaccines in animal models have shown that it can be effective against Omicron but not so much against past variants. As long as past variants exist, such as Delta still being prominent in parts of the globe, it is important to remind ourselves that an Omicron-updated vaccine would not be sufficient on its own but could be an option in combination, or as a booster, with existing vaccines.\u201d
One question that may arise is regarding the necessity of an Omicron-specific vaccine if scientists do not know what comes next.
For that reason, recent studies have focused on a pan-coronavirus or \u201cuniversal\u201d vaccine<\/a> that targets the whole virus and not just the ever-mutating spike protein.
***Semih Tareen is a virologist, and any opinions expressed are solely his own and do not express the views or opinions of his employer.<\/em>
For live updates on the latest developments regarding COVID-19, click here<\/a>.<\/em><\/strong>
In this Snapshot feature, we look at what we know about symptoms of infection with Omicron, home treatments, and prevention measures.<\/a>
As the Omicron variant of SARS-CoV-2 keeps spreading, one question remains: Will COVID-19 vaccines be able to stand against it? We investigate.<\/a>
A subvariant of Omicron called BA.2, which some refer to as the 'stealth variant,' has stirred public health experts' interests. Why is that, and\u2026<\/a>
Experts have detected a new variant of SARS-CoV-2 in southern Africa, Hong Kong, and Europe. Here, we explain what we know about Omicron so far.<\/a>
OUR BRANDS<\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our coronavirus hub and follow our live updates page for the most recent information on the COVID-19 pandemic.It is unlikely that Omicron will end the pandemic as we know it or be […]<\/p>\n","protected":false},"author":869,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/1956"}],"collection":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/users\/869"}],"replies":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/comments?post=1956"}],"version-history":[{"count":0,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/1956\/revisions"}],"wp:attachment":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/media?parent=1956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/categories?post=1956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/tags?post=1956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}